NasdaqGS:UTHRBiotechs
Tyvaso IPF Trial Win Amid Revenue Miss Could Be A Game Changer For United Therapeutics (UTHR)
United Therapeutics recently reported a weaker-than-expected first quarter, with revenue declining year on year and falling short of analyst forecasts, leading to an earnings-per-share outcome that lagged peers.
At the same time, the company reported positive TETON-1 Phase 3 results for nebulized Tyvaso in idiopathic pulmonary fibrosis and pursued unconventional R&D avenues, including microgravity-based pharmaceutical processing with Varda Space Industries, underscoring a contrast between...